Anti-neutrophil cytoplasmic antibody-associated vasculitis

This phase 2 trial is testing whether a new drug called obinutuzumab beta, combined with a short course of steroids, can help people with newly diagnosed ANCA-associated glomerulonephritis—a rare autoimmune disease that causes kidney inflammation and damage. The study will enroll…

This trial tests an investigational cell therapy called FT839 in people with active autoimmune diseases, including ANCA-associated vasculitis, inflammatory myositis, rheumatoid arthritis, lupus, and systemic sclerosis. Participants receive FT839 as two intravenous infusions, some…

This study is checking the long-term safety of a drug called avacopan for people with ANCA-associated vasculitis, a rare disease where the immune system attacks blood vessels. About 300 adults who need treatment for a new diagnosis or flare-up will take avacopan or a placebo. The…

This Phase 2 trial tests whether adding ALE.F02 to standard therapy can protect kidney function in people with ANCA-associated vasculitis, an autoimmune disease that attacks small blood vessels, often damaging the kidneys. About 80 participants will receive either a low, high, or…

This Phase 3 trial is testing whether adding BDB-001 to standard treatments (cyclophosphamide, azathioprine, rituximab, or prednisone) helps more people with ANCA-associated vasculitis achieve remission. The study plans to enroll 300 adults with active GPA or MPA. Participants wi…

This study tests a new treatment called NKX019 for people with autoimmune diseases like systemic sclerosis, rheumatoid arthritis, and vasculitis. NKX019 uses specially engineered immune cells to target and calm overactive B cells that cause the disease. The goal is to see if it i…

This early study tests whether a liquid form of the drug avacopan can be safely given through a feeding tube to critically ill patients with ANCA vasculitis who have severe lung bleeding and need a ventilator. The main goal is to measure how the drug levels change in the blood ov…

This early-stage study tests a new treatment called RD06-05, a universal CAR-T cell therapy, in up to 84 adults with autoimmune diseases like lupus, vasculitis, and scleroderma. The therapy targets and removes faulty immune cells to help control the disease. The main goal is to c…

This early-stage trial is testing Descartes-08, a cell therapy made from modified immune cells, in 50 young people aged 12 and older with four autoimmune diseases: childhood-onset lupus, ANCA-associated vasculitis, juvenile myasthenia gravis, and juvenile dermatomyositis. The stu…

This early-stage trial tests a new therapy called FKC289, which uses a patient's own immune cells engineered to target two proteins (BCMA and CD19) on cells that drive autoimmune attacks. The goal is to see if it is safe and can help control kidney diseases like lupus nephritis a…

This trial investigates whether pioglitazone, a drug used for diabetes, can help protect the kidneys in people with ANCA-associated vasculitis—a rare autoimmune disease that causes inflammation of blood vessels, often damaging the kidneys. Participants receive either pioglitazone…

This early-phase trial is testing a new drug called MTS109, made with mRNA technology, for people with moderate to severe autoimmune diseases like lupus and scleroderma. Fifteen participants will receive several injections over a month to see if it is safe and tolerable. The goal…

This study tests a new drug called tarperprumig in 75 adults with ANCA-associated vasculitis, a rare disease where the immune system attacks blood vessels. The goal is to see if the drug is safe and can help control the disease by reducing inflammation. Participants will receive …

This early-stage study is testing a new cell therapy called FT819 for people with severe autoimmune diseases like lupus, vasculitis, and scleroderma. The treatment involves giving specially engineered immune cells along with chemotherapy drugs. The main goal is to see if it's saf…

This study tests a new treatment called QT-219CX, which uses specially engineered immune cells (CAR-T cells) to target and calm the overactive immune system in people with autoimmune diseases like lupus, kidney disease, and scleroderma. The treatment is given as a one-time infusi…

This early study is testing a new treatment called CD19 CAR-T therapy for people with severe autoimmune diseases like lupus and scleroderma that haven't improved with standard medications. The therapy involves taking a patient's own immune cells, reprogramming them to target and …

This phase 3 trial is for people with granulomatosis with polyangiitis (GPA), a rare autoimmune disease causing blood vessel inflammation, who did not get better with standard treatments. It compares three salvage therapies: rituximab plus another drug, tocilizumab, or tofacitini…

This early-phase trial is testing a new type of cell therapy called QT-219C, which uses donor-derived CAR-T cells to target and destroy faulty immune cells in people with severe autoimmune diseases like lupus, nephrotic syndrome, and vasculitis. The study will enroll 15 participa…

This early-phase trial is testing a personalized cell therapy called CAR-T, designed to target and destroy faulty immune cells in people with active autoimmune diseases like lupus, scleroderma, and Sjogren's syndrome. Up to 20 participants will receive the treatment after a short…

This early-stage study tests a new cell therapy called YTS109 in 18 adults aged 18-65 with autoimmune diseases like lupus and Sjogren's syndrome that have not responded to standard treatments. Participants receive a single infusion of the cells, and researchers monitor safety and…

This early-stage trial is testing a new treatment called YTS109 for people with severe autoimmune diseases like lupus and Sjogren's syndrome that have come back or not responded to standard care. About 18 adults will receive a single infusion of these specially engineered immune …

This early-stage study tests a new cell therapy called YTS109 in 18 adults with severe autoimmune diseases like lupus and Sjogren's syndrome that have not responded to standard treatments. Participants receive a single infusion of the cells, and researchers monitor safety and how…

This early-stage study tests a new cell treatment called YTS109 in 18 adults with hard-to-treat autoimmune diseases like lupus and scleroderma. Participants receive a single infusion of these specially designed cells. The main goal is to check if the treatment is safe, and also t…

This early-phase study tests a new type of CAR-T cell therapy (called KN3601) for people with severe autoimmune diseases like lupus, scleroderma, Sjögren's syndrome, rheumatoid arthritis, and vasculitis that haven't responded to standard treatments. The therapy uses specially eng…

This early-phase study tests a new treatment called TI-0032-III for people with severe autoimmune diseases like lupus and scleroderma that haven't improved with standard care. The treatment uses a special injection to create CAR-T cells inside the body, which then target and dest…

This early-stage study is testing a universal donor CAR T-cell therapy that targets two proteins (CD19 and BCMA) on immune cells that drive autoimmune diseases. The goal is to see if it is safe and can help control conditions like lupus, kidney disease, and vasculitis. About 15 p…

This early-phase study tests a new treatment called RD06-05, which uses a patient's own immune cells modified to target and reset the immune system in autoimmune diseases like lupus, multiple sclerosis, and vasculitis. The goal is to check safety and how well the body tolerates i…

This phase 3 trial is testing whether a 4-week low-dose steroid regimen, given alongside standard drugs like rituximab or cyclophosphamide, is safer and as effective as the usual longer steroid treatment for ANCA vasculitis with severe kidney problems. The study will enroll 36 pe…

This early-stage study is testing a new type of cell therapy (called QT-019C) in 12 adults with severe autoimmune diseases like lupus and scleroderma that have not responded to standard treatments. The therapy uses specially engineered immune cells from a healthy donor to target …

This study tests a new treatment using specially engineered immune cells (CAR-NK) from cord blood for people with severe autoimmune diseases like lupus, scleroderma, and vasculitis that haven't responded to standard therapies. The goal is to see if it's safe and can control the d…

This early-phase trial is testing a personalized immune cell therapy called CD19 CAR-T in 15 people with severe autoimmune diseases like lupus and scleroderma that haven't responded to standard treatments. The therapy aims to temporarily deplete certain immune cells to calm the o…

This early-stage study tests a new treatment for people with severe autoimmune diseases like lupus and scleroderma that haven't improved with standard therapies. The treatment uses specially engineered immune cells (CAR T-cells) from a healthy donor to target and potentially rese…

This study is testing a new type of PET scan tracer (68Ga-FAPI) to see if it can better detect lung and kidney problems in people with ANCA-associated vasculitis, a rare autoimmune disease. The tracer targets specific cells linked to tissue scarring. Researchers will enroll 30 ad…

This study is testing a new blood-based test that aims to predict which medication will work best for each person with rheumatic diseases like rheumatoid arthritis or lupus. Researchers will take a blood sample and analyze immune cells to create a personalized treatment profile. …

This study aims to better understand why some people's immune cells attack their own body, causing autoimmune diseases like lupus and scleroderma. Researchers will analyze blood samples from 200 adults with these conditions to identify and measure specific harmful immune cells. T…

This study follows up to 4,000 people with vasculitis (a group of diseases that cause blood vessel inflammation) and healthy volunteers over many years. Researchers collect blood, urine, imaging, and genetic samples to learn how the disease develops and changes. The goal is to fi…

This study investigates how changes in kidney cell metabolism relate to the rate of kidney function decline in people with ANCA vasculitis and other kidney diseases. Researchers will analyze kidney biopsy samples and blood/urine tests from 146 participants over one year. The goal…

This study is collecting blood, urine, and fecal samples from 100 people with ANCA-associated vasculitis, a rare autoimmune disease. Researchers will follow participants for up to 5 years, tracking relapses and complications. The goal is to identify factors that predict disease f…

This study aims to learn how well heart scans (MRI, ultrasound, PET) can detect and predict outcomes in people with suspected or known inflammatory heart diseases. Researchers will follow 5,000 adults for one year to see how often heart involvement is confirmed and how it affects…

This study is testing whether a special full-body PET scan can more accurately detect active ANCA-associated vasculitis (AAV) and predict long-term heart disease risk. Researchers will scan up to 120 participants (some with active AAV, some healthy) using three different tracers …